Drug Discovery & Pharmaceuticals

RSS

New computational protocol accelerates drug discovery for Chagas disease

Researchers at the University of Kent have established a computational protocol that could accelerate the development of more effective treatments for life-threatening parasitic infections such as Chagas disease, by enabling scientists to accurately identify reactions that can result in successful drug candidates without the need for trial and error.

25 Apr 2026

AI model rapidly designs new antibiotic to fight resistant bacteria

Researchers at McMaster University have developed a new generative artificial intelligence (AI) model capable of drastically speeding up drug discovery - and, in early tests, it has already designed a brand-new antibiotic.

23 Apr 2026

Researchers receive NIH grant to accelerate Alzheimer's drug discovery efforts

Dr. Damian Young, investigator at Texas Children's Duncan Neurological Research Institute (Duncan NRI) and director of the Center for Drug Discovery at Baylor College of Medicine, along with collaborators has been awarded a $6.7 million grant from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to develop new approaches to rapidly identify potential treatments for Alzheimer's disease and related dementias with the goal of accelerating the discovery of new therapies.

23 Apr 2026

Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models

Atelerix, a biotech company revolutionizing cell preservation and biological transport with its pioneering hydrogel encapsulation technology, today announced the launch of STORganoid™, an ambient-temperature preservation solution for organoids and spheroids.

From Atelerix Ltd 21 Apr 2026

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

AlzeCure Pharma AB (publ), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that the last patient’s last visit (LPLV) has now occurred in the ongoing Phase Ib clinical trial of ACD856, the lead drug candidate within the NeuroRestore platform, which is being developed for Alzheimer’s disease and other indications.

From AlzeCure Pharma AB 21 Apr 2026

Why AI is becoming a powerful tool in cancer drug discovery

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical translation, with an AI-designed TNIK inhibitor trial serving as an important proof-of-feasibility reference point. It argues that precision oncology could benefit from AI-driven integration of multi-omics, federated learning, and adaptive trial design, but only if validation, fairness, interpretability, and regulatory alignment improve.

16 Apr 2026

Waters debuts industry-first extended-range MALS detector for UHPLC/UPLC, powering rapid characterization of large molecules

Waters Corporation today announced the launch of the Waters omniDAWN™ Multi-Angle Light Scattering (MALS) Photometer, part of the Wyatt Technology Portfolio.

From Waters Corporation 16 Apr 2026

ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery

ORGAPRED, a France-based core facility specializing in Patient-Derived Tumor Organoid (PDTO) research, has selected the CYTOQUBE high-throughput 3D imaging system from Hamamatsu Photonics France to support personalized oncology drug screening and therapeutic discovery.

From Hamamatsu Photonics Europe 15 Apr 2026

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostics products, today extended its range of recombinant monoclonal anti-idiotypic antibodies, with the introduction of eight antibodies specific to romosuzumab (Evenity), burosumab (Crysvita), ixekizumab (Taltz), elotuzumab (Empliciti), isatuximab (Sarclisa), nirsevimab (Beyfortus), and tremelimumab (Imjudo), and released a recombinant monoclonal anti-biotherapeutic antibody specific to dulaglutide (Trulicity).

From Bio-Rad Laboratories 15 Apr 2026

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

VALANX Biotech (VALANX), a biotech company developing novel technology for site-specific protein conjugation in drug discovery, today announced the formation of its Scientific Advisory Board (SAB), appointing John Lambert as Chair, with Morris Rosenberg and Peter de Waele serving alongside.

From VALANX Biotech 15 Apr 2026

ELRIG announces inaugural US drug discovery conference

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, today announced the launch of Drug Discovery USA 2026.

From ELRIG (UK) Ltd. 15 Apr 2026

Expanded assay development and screening services strengthen integrated drug discovery capabilities

Concept Life Sciences' expanded Assay Development and Screening services enhance drug discovery, reinforcing our commitment to innovative therapeutic solutions.

From Concept Life Sciences 14 Apr 2026

Novel antibiotic compound shows promise against MRSA skin infections

The development of new antibiotics to treat superbugs and other bacterial infections is a global priority, with the rate of infections that cannot be treated with current antibiotics rising and presenting one of the biggest threats to human health.

11 Apr 2026

Alligator Bioscience provides an update on mitazalimab

Alligator Bioscience, a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today provided a brief update regarding mitazalimab.

From Alligator Bioscience 11 Apr 2026

AI-powered chemistry accelerates discovery of selective cancer inhibitors

Recently, the Insilico team's research entitled "An Internal Sulfur-Lone Pair Interaction Enabled the Discovery of Potential and Sub-Family Selective PKMYT1 Inhibitors" was invited for publication as a cover Feature in ChemMedChem.

9 Apr 2026

Novel catalytic approach accelerates synthesis of branched drug compounds

When chemists design drug candidates, shape matters enormously. Many active pharmaceutical ingredients contain branched carbon structures-points where the molecular chain forks in a specific direction-that are critical to whether a molecule will bind to its biological target and whether it will be safe.

9 Apr 2026

UVA scientists develop AI tools to accelerate new drug discovery

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery that could dramatically accelerate the creation of new medicines.

9 Apr 2026

Sponge and sea slug partnership yields a new anticancer molecule with drug design promise

Researchers identified jorumycidine, a new hexacyclic marine alkaloid from the nudibranch Jorunna funebris and its dietary sponge, Haliclona sp., and demonstrated that it exhibits potent nanomolar cytotoxicity against multiple myeloma cells. They also proposed a new biosynthetic route involving cross-species metabolic interplay and an unusual oxazolidine ring that may help stabilize a pharmacologically important scaffold.

8 Apr 2026

New compounds reduce inflammation without weakening immune defense

Scripps Research scientists have developed a new class of drug compounds that reduce harmful inflammation while leaving the body's ability to fight infections intact-a long-sought goal in treating autoimmune diseases.

6 Apr 2026

AI helps researchers find antimicrobial peptides in Earth’s harshest habitats

Researchers built the Extreme Environment Microbiome Catalog from 78,213 genomes across global extreme habitats, revealing major taxonomic and biosynthetic novelty, including 32,715 representative species, nearly 4 billion non-redundant genes, and 163,693 biosynthetic gene clusters. They then used protein language models to identify 3,032 candidate non-toxic antimicrobial peptides, with 84 of 100 synthesized peptides showing antibacterial activity and low cytotoxicity in the 50 tested in mammalian cells.

6 Apr 2026

Drug Discovery & Pharmaceuticals

New computational protocol accelerates drug discovery for Chagas disease

AI model rapidly designs new antibiotic to fight resistant bacteria

Researchers receive NIH grant to accelerate Alzheimer's drug discovery efforts

Atelerix launches STORganoid cryo-free preservation solution for complex 3D cell models

Last patient has completed AlzeCure's Phase Ib clinical study with NeuroRestore ACD856

Why AI is becoming a powerful tool in cancer drug discovery

Waters debuts industry-first extended-range MALS detector for UHPLC/UPLC, powering rapid characterization of large molecules

ORGAPRED selects CYTOQUBE® from Hamamatsu Photonics for personalized oncology research and therapeutic discovery

Bio-Rad extends range of anti-idiotypic antibodies and anti-Fc mutation antibodies for bioanalysis and drug monitoring

VALANX Biotech establishes Scientific Advisory Board to advance ADC therapeutics

ELRIG announces inaugural US drug discovery conference

Expanded assay development and screening services strengthen integrated drug discovery capabilities

Novel antibiotic compound shows promise against MRSA skin infections

Alligator Bioscience provides an update on mitazalimab

AI-powered chemistry accelerates discovery of selective cancer inhibitors

Novel catalytic approach accelerates synthesis of branched drug compounds

UVA scientists develop AI tools to accelerate new drug discovery

Sponge and sea slug partnership yields a new anticancer molecule with drug design promise

New compounds reduce inflammation without weakening immune defense

AI helps researchers find antimicrobial peptides in Earth’s harshest habitats

How Pulp Fixin Is Turning Paper into High-Performance Sustainable Labware

A new method to measure intracellular water in biological systems

Obesity, GLP-1s, and metabolic care

Latest Life Science News